Treatable Traits in Systemic Sclerosis
- PMID: 37603199
- DOI: 10.1007/s12016-023-08969-x
Treatable Traits in Systemic Sclerosis
Abstract
Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a "treatable trait" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.
Keywords: Autoimmune disorder; Systemic sclerosis; Treatable trait.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.Front Immunol. 2023 Sep 11;14:1246777. doi: 10.3389/fimmu.2023.1246777. eCollection 2023. Front Immunol. 2023. PMID: 37753072 Free PMC article.
-
Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.Rheumatol Int. 2019 Nov;39(11):1841-1848. doi: 10.1007/s00296-019-04402-9. Epub 2019 Aug 2. Rheumatol Int. 2019. PMID: 31375891
-
Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels.Autoimmun Rev. 2020 May;19(5):102515. doi: 10.1016/j.autrev.2020.102515. Epub 2020 Mar 12. Autoimmun Rev. 2020. PMID: 32173517
-
The contemporary management of systemic sclerosis.Expert Rev Clin Immunol. 2018 Jul;14(7):573-582. doi: 10.1080/1744666X.2018.1485490. Epub 2018 Jun 20. Expert Rev Clin Immunol. 2018. PMID: 29874475 Review.
-
Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).Front Immunol. 2020 Sep 4;11:1990. doi: 10.3389/fimmu.2020.01990. eCollection 2020. Front Immunol. 2020. PMID: 33013852 Free PMC article. Review.
Cited by
-
Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.BMJ Open Respir Res. 2024 Mar 13;11(1):e002161. doi: 10.1136/bmjresp-2023-002161. BMJ Open Respir Res. 2024. PMID: 38479818 Free PMC article.
-
Walking the path of treatable traits in interstitial lung diseases.Respir Res. 2023 Oct 24;24(1):251. doi: 10.1186/s12931-023-02554-8. Respir Res. 2023. PMID: 37872563 Free PMC article.
-
Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.RMD Open. 2024 Sep 20;10(3):e004492. doi: 10.1136/rmdopen-2024-004492. RMD Open. 2024. PMID: 39306344 Free PMC article.
References
-
- Cavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E, Lazzaroni MG, Garrafa E, Franceschini F (2022) Systemic sclerosis-specific antibodies: novel and classical biomarkers. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-022-08946-w - DOI - PubMed - PMC
Publication types
LinkOut - more resources
Full Text Sources